Literature DB >> 34858116

THE VALUE OF A REGIONAL 'LIVING' COVID-19 REGISTRY AND THE CHALLENGES OF KEEPING IT ALIVE.

John Hanna, Tara Chen, Carlos Portales-Castillo, Mina Said, Rene Bulnes, Donna Newhart, Lucas Sienk, Katherine Schantz, Kathleen Rozzi, Karan Alag, Jonathan Bress, Emil Lesho DO.   

Abstract

Background: The availability of accurate, reliable, and timely clinical data is crucial for clinicians, researchers, and policymakers so that they can respond effectively to emerging public health threats. This was typified by the recent SARS-CoV-2 pandemic and the critical knowledge and data gaps associated with novel Coronavirus 2019 disease (COVID-19).We sought to create an adaptive, living data mart containing detailed clinical, epidemiologic, and outcome data from COVID-19 patients in our healthcare system. If successful, the approach could then be used for any future outbreak or disease.
Methods: From 3/13/2020 onward, demographics, comorbidities, outpatient medications, along with 75 laboratory, 2 imaging, 19 therapeutic, and 4 outcome-related parameters, were manually extracted from the electronic medical record (EMR) of SARS-CoV-2 positive patients. These parameters were entered on a registry featuring calculation, graphing tools, pivot tables, and a macro programming language. Initially, two internal medicine residents populated the database, then professional data abstractors populated the registry. Clinical parameters were developed with input from infectious diseases and critical care physicians and using a modified COVID-19 worksheet from the U.S. Centers for Disease Control and Prevention (CDC). Registry contents were migrated to a browser-based, metadata-driven electronic data capture software platform. Eventually, we developed queries and used various business intelligence (BI) tools which enabled us to semi-automate data ingestion of 147 clinical and outcome parameters from the EMR, via a large U.S. hospital-based, service-level, all-payer database. Statistics were performed in R and Minitab.
Results: From March 13, 2020 to May 17, 2021, 549,691 SARS-CoV-2 test results on 236,144 distinct patients, along with location, admission status, and other epidemiologic details are stored on the cloud-based BI platform. From March 2020 until May 2021, extraction of clinical-epidemiologic parameter had to be performed manually. Of those, 543 have had >/=75 parameters fully entered in the registry. Ten clinical characteristics were significantly associated with the need for hospital admission. Only one characteristic was associated with a need for ICU admission. Use of supplemental oxygen, vasopressors and outpatient statin were associated with increased mortality.Initially, 0.5hrs -1.5 hours per patient chart (approximately 450-575 person hours) were required to manually extract the parameters and populate the registry. As of May 17, 2021, semi-automated data ingestion from the U.S. hospital all-payer database, employing user-defined queries, was implemented. That process can ingest and populate the registry with 147 clinical, epidemiologic, and outcome parameters at a rate of 2 hours per 100 patient charts.
Conclusion: A living COVID-19 registry represents a mechanism to facilitate optimal sharing of data between providers, consumers, health information networks, and health plans through technology-enabled, secure-access electronic health information. Our approach also involves a diversity of new roles in the field, such as using residents, staff, and the quality department, in addition to professional data extractors and the health informatics team.Initially, due to the overwhelming number of infections that continues to accelerate, and the labor/time intense nature of the project, only a small fraction of all patients with COVID-19 had all parameters entered in the registry. Therefore, this report also offers lessons learned and discusses sustainability issues, should others wish to establish a registry. It also highlights the registry's local and broader public health significance. Beginning in June 2021, whole-genome sequencing results such as lineages harboring important viral mutations, or variants of concern will be linked to the clinical meta-data.
Copyright © 2021 by the American Health Information Management Association.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; electronic medical record; epidemiology; genomic epidemiology; genomics; mortality; registry

Mesh:

Year:  2021        PMID: 34858116      PMCID: PMC8580456     

Source DB:  PubMed          Journal:  Perspect Health Inf Manag        ISSN: 1559-4122


  9 in total

1.  The antimicrobial resistance monitoring and research (ARMoR) program: the US Department of Defense response to escalating antimicrobial resistance.

Authors:  Emil P Lesho; Paige E Waterman; Uzo Chukwuma; Kathryn McAuliffe; Charlotte Neumann; Michael D Julius; Helen Crouch; Ruvani Chandrasekera; Judith F English; Robert J Clifford; Kent E Kester
Journal:  Clin Infect Dis       Date:  2014-05-01       Impact factor: 9.079

2.  Failing the Test - The Tragic Data Gap Undermining the U.S. Pandemic Response.

Authors:  Eric C Schneider
Journal:  N Engl J Med       Date:  2020-05-15       Impact factor: 91.245

3.  In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19.

Authors:  Xiao-Jing Zhang; Juan-Juan Qin; Xu Cheng; Lijun Shen; Yan-Ci Zhao; Yufeng Yuan; Fang Lei; Ming-Ming Chen; Huilin Yang; Liangjie Bai; Xiaohui Song; Lijin Lin; Meng Xia; Feng Zhou; Jianghua Zhou; Zhi-Gang She; Lihua Zhu; Xinliang Ma; Qingbo Xu; Ping Ye; Guohua Chen; Liming Liu; Weiming Mao; Youqin Yan; Bing Xiao; Zhigang Lu; Gang Peng; Mingyu Liu; Jun Yang; Luyu Yang; Changjiang Zhang; Haofeng Lu; Xigang Xia; Daihong Wang; Xiaofeng Liao; Xiang Wei; Bing-Hong Zhang; Xin Zhang; Juan Yang; Guang-Nian Zhao; Peng Zhang; Peter P Liu; Rohit Loomba; Yan-Xiao Ji; Jiahong Xia; Yibin Wang; Jingjing Cai; Jiao Guo; Hongliang Li
Journal:  Cell Metab       Date:  2020-06-24       Impact factor: 27.287

4.  Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019.

Authors:  Reed Magleby; Lars F Westblade; Alex Trzebucki; Matthew S Simon; Mangala Rajan; Joel Park; Parag Goyal; Monika M Safford; Michael J Satlin
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

5.  Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.

Authors:  Katherine Mackey; Valerie J King; Susan Gurley; Michael Kiefer; Erik Liederbauer; Kathryn Vela; Payten Sonnen; Devan Kansagara
Journal:  Ann Intern Med       Date:  2020-05-15       Impact factor: 25.391

6.  Remdesivir for the Treatment of Covid-19 - Final Report.

Authors:  John H Beigel; Kay M Tomashek; Lori E Dodd; Aneesh K Mehta; Barry S Zingman; Andre C Kalil; Elizabeth Hohmann; Helen Y Chu; Annie Luetkemeyer; Susan Kline; Diego Lopez de Castilla; Robert W Finberg; Kerry Dierberg; Victor Tapson; Lanny Hsieh; Thomas F Patterson; Roger Paredes; Daniel A Sweeney; William R Short; Giota Touloumi; David Chien Lye; Norio Ohmagari; Myoung-Don Oh; Guillermo M Ruiz-Palacios; Thomas Benfield; Gerd Fätkenheuer; Mark G Kortepeter; Robert L Atmar; C Buddy Creech; Jens Lundgren; Abdel G Babiker; Sarah Pett; James D Neaton; Timothy H Burgess; Tyler Bonnett; Michelle Green; Mat Makowski; Anu Osinusi; Seema Nayak; H Clifford Lane
Journal:  N Engl J Med       Date:  2020-10-08       Impact factor: 91.245

7.  What the Coronavirus Disease 2019 (COVID-19) Pandemic Has Reinforced: The Need for Accurate Data.

Authors:  Simone Arvisais-Anhalt; Christoph U Lehmann; Jason Y Park; Ellen Araj; Michael Holcomb; Andrew R Jamieson; Samuel McDonald; Richard J Medford; Trish M Perl; Seth M Toomay; Amy E Hughes; Melissa L McPheeters; Mujeeb Basit
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

8.  Living systematic reviews: an emerging opportunity to narrow the evidence-practice gap.

Authors:  Julian H Elliott; Tari Turner; Ornella Clavisi; James Thomas; Julian P T Higgins; Chris Mavergames; Russell L Gruen
Journal:  PLoS Med       Date:  2014-02-18       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.